Join
Live feed
·
PRReleasevia Quantisnow
GSK plc logo

GSK's RSV Vaccine, AREXVY, Approved in US for Expanded Age Indication in Adults Aged 18–49 Years at Increased Risk

ByQuantisnow·Wall Street's wire, on your screen.
GSK· GSK plc
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track GSK (GSK plc) and more on Quantisnow.